CVS
39
-4
MHK
48
6
JNPR
45
2
DLTR
38
4
ITW
52
-3
INTU
68
2
BIIB
33
-6
KEY
64
6
LH
48
2
PRGO
33
-2
AEE
48
-3
IPG
49
2
KSS
46
3
CRM
54
4
OI
45
3
CCI
54
7
FOX
20
-13
APD
47
-3
GME
55
13
VNO
63
4
CVS
39
-4
MHK
48
6
JNPR
45
2
DLTR
38
4
ITW
52
-3
INTU
68
2
BIIB
33
-6
KEY
64
6
LH
48
2
PRGO
33
-2
AEE
48
-3
IPG
49
2
KSS
46
3
CRM
54
4
OI
45
3
CCI
54
7
FOX
20
-13
APD
47
-3
GME
55
13
VNO
63
4
Financhill
Back

Apellis Pharmaceuticals 10K Form

Buy
54

APLS
Apellis Pharmaceuticals

Last Price:
53.88
Seasonality Move:
8.4%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive APLS News And Ratings

See the #1 stock for the next 7 days that we like better than APLS

APLS Financial Statistics

Sales & Book Value

Annual Sales: $75.42M
Cash Flow: $-169.13M
Price / Cash Flow: 0
Annual Sales: $1.96
Price / Book: 25.66

Profitability

EPS (TTM): -5.25000
Net Income (TTM): $-606.04M
Gross Margin: $69.79M
Return on Equity: -206.55%
Return on Assets: -69.73%

Apellis Pharmaceuticals Earnings Forecast

Key Apellis Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 5 years for APLS is 92.54%.
  • The Selling, General & Administrative Expenses for APLS have been equal to 367.49% of Gross Profit Margin.
  • The Research & Development expenses have been 513.44% of Revenue.
  • The Interest Expense is -5.00% of Operating Income.
  • The Net Earning history of APLS is -864.72% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 4 years.

Apellis Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
Current Symbol: APLS
CUSIP: 03753U
Website: apellis.com

Debt

Debt-to-Equity Ratio: 0.4
Current Ratio: 4.29
Quick Ratio: 3.44

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

APLS Technical Analysis vs Fundamental Analysis

Buy
54
Apellis Pharmaceuticals (APLS) is a Buy

Is Apellis Pharmaceuticals a Buy or a Sell?